6 active trials 0 recruiting 3 Phase 3 1 disease areas
| Phase 1 | 1 | |
| Phase 2 | 2 | |
| Phase 3 | 3 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | Primary Myelofibrosis | Active, Not Recruiting | 2026-08-13 |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With… | Essential Thrombocythemia | Active, Not Recruiting | 2026-07-22 |
| NCT05481151 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | Polycythemia Vera | Active, Not Recruiting | 2025-08-13 |
| Phase 2 | ||||
| NCT05482971 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101… | Essential Thrombocythemia | Active, Not Recruiting | 2025-08-13 |
| NCT05485948 | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant… | Polycythemia Vera | Active, Not Recruiting | 2025-08-03 |
| Phase 1 | ||||
| NCT07053904 | Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | Advanced Solid Tumors | Enrolling by Invitation | 2025-07-08 |
Myelofibrosis (1)